Professor Oak

1/8 🚨 New preprint from the @SternbergLab & Jinek labs! CRISPR-associated transposases (CASTs) insert large DNA cargoes at precise genomic locations — no double-strand breaks needed.

Expect more of this Interesting implications not only for China but also for domestic fast-followers... how can you have confidence in your head-to-head functional assay if you don't know you made the right comparator?

So we’re all just ignoring the hundreds of millions of dollars worth of biobucks + royalties + China rights + NewCo equity?

Autonomous science promises to augment scientific discovery, but current LLMs tend to mode collapse into low-diversity generations. We introduce “Unlocking LLM Creativity in Science through Analogical Reasoning”, which uses analogies to generate better candidate solutions! [1/N]

Speaking of, ENTIRELY too much in vivo CAR-T this year. Hundreds of abstracts, of which just a few piqued my interest Kelonia $LLY BCMA-LVV non-clin data de-risk key specificity Q’s for LVV, as profile - in terms of both transduction & expression - looks v clean (#2264) $OPK CD3xCD28-targeted LNP to deliver CD19 CAR mRNA, an interesting strategy to enhance specificity & T cell activation (#338) $SNY tLNP-CD19 CAR (#343) reminded me Tidal M&A was in 2021! 3-5 yrs before all of pharma aped in, yet hopelessly behind today… (19/21)

Letting AI carry us on over to “C”… Inaugural data release from Lila, the company “building scientific superintelligence to solve humankind’s greatest challenges,” is... an in vivo CD20 CAR-T! (#3251) Even the road to a new age of boundless discovery has to start somewhere, I guess (18/21)

Due to popular demand, after a brief hiatus, Oak’s ASGCT abstract dump is back - now it’s 5th installment, better than ever Posting later than I’d hoped - still shaking off the rust - but the show must go on; & what’s better than starting ASGCT Day 2 with the thread you needed 2 weeks ago? (1/21)